FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a pharmaceutical multiparticulate-type dosage form. The declared dosage form contains one or more sets of synchronised pulse release (SPR) granules of a weakly alkaline drug wherein the weakly alkaline drug contains a nitrogen (N) containing selective 5-HT3 serotonin antagonist or a pharmaceutically acceptable salt thereof, having a pKa within the range from approximately 5 to approximately 14 and a solubility of no more than approximately 200 mg/ml at pH 6.8. The above SPR granules comprise the particles with organic acid nuclei coated with a film providing a release time delay. Also, the invention refers to a method for preparing a pharmaceutical dosage forms.
EFFECT: invention provides achieving the adequate plasma drug concentration 24 hours after the dose intake that makes it applicable for the OD regimen.
39 cl, 10 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SYSTEMS OF DELIVERING MEDICAL SUBSTANCES, INCLUDING WEAKLY BASIC MEDICINAL SUBSTANCES AND ORGANIC ACIDS | 2009 |
|
RU2504362C2 |
| SYSTEMS OF MEDICATION DELIVERY, CONTAINING WEAK-BASE MEDICATIONS AND ORGANIC ACIDS | 2007 |
|
RU2428176C2 |
| SYSTEMS OF MEDICATION DELIVERY, INCLUDING SOLID SOLUTIONS OF WEAK-BASE MEDICATIONS | 2007 |
|
RU2434630C2 |
| TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | 2014 |
|
RU2674345C2 |
| DELAYED FIXED-TIME PULSATILE RELEASE DOSAGE FORMS | 2008 |
|
RU2452472C2 |
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| PHARMACEUTICAL FORM FOR DRUG DELIVERY TO THE COLON | 2007 |
|
RU2646825C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| COMPOSITIONS CONTAINING WEAKLY BASIC DRUG SUBSTANCES, AND CONTROLLED-RELEASE DOSAGE FORMS | 2009 |
|
RU2548748C2 |
| METHOD OF ANTIDEMENTIA DRUG STABILISATION | 2005 |
|
RU2401125C2 |
